ArticleFrontiers in immunology2026
Linoleic acid metabolic reprogramming is linked to immunometabolic remodeling and post-transplant recurrence risk in hepatocellular carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipids serve as both metabolic substrates and signaling mediators that critically regulate immune cell fate, function, tolerance, and intercellular communication. In hepatocellular carcinoma (HCC), it remains unclear how intratumoral linoleic acid (LA) allocation between desaturation and oxidative catabolism influences immunometabolic remodeling and post-transplant recurrence. Methods: Multi-omics profiling was conducted in a liver transplant-associated HCC cohort using paired tumor/non-tumor tissues and serum samples. The intratumoral lipid milieu (C4-C24 fatty acids) was quantified by targeted gas chromatography, whereas lipid-immune programs were resolved by single-nucleus RNA sequencing (snRNA-seq) integrated with targeted transcriptomic profiling. Key immune phenotypes and candidate genes were validated by serum inflammatory mediator profiling, flow cytometric lymphocyte immunophenotyping, spatially resolved tissue assays, and qRT-PCR. LA perturbation experiments provided functional support Result: Fatty acid profiling revealed that non-recurrent tumors were characterized by a higher intratumoral LA/AA ratio and a lower estimated Δ6-desaturation index than recurrent tumors, whereas recurrent tumors exhibited a higher estimated Δ6-desaturation index than their matched distant non-tumor liver tissues. snRNA-seq identified fatty acid catabolism as the most prominently downregulated metabolic pathway in recurrent tumors; malignant-cell analysis further highlighted EHHADH and ACSL3 as key genes involved in recurrence-associated lipid metabolic remodeling. Conclusion: Multi-omics analyses indicate that, in primary pre-transplant HCC, post-transplant recurrence is associated with an imbalance between a higher estimated Δ6-desaturation index and attenuated oxidative catabolism-related features of linoleic acid, accompanied by Treg-associated immunosuppressive remodeling. These findings provide a biologically informed framework for post-transplant recurrence risk stratification and further translational investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.